keyword
MENU ▼
Read by QxMD icon Read
search

Infliximab therapeutic drug monitoring

keyword
https://www.readbyqxmd.com/read/28593609/therapeutic-drug-monitoring-tdm-as-a-tool-in-the-switch-from-infliximab-innovator-to-biosimilar-in-rheumatic-patients-results-of-a-12-month-observational-prospective-cohort-study
#1
E M H Schmitz, S Benoy-De Keuster, A J L Meier, V Scharnhorst, R A M Traksel, M A C Broeren, L J J Derijks
The objective of this study is to apply therapeutic drug monitoring (TDM) as an objective tool to monitor the switch from infliximab innovator (INX) to infliximab biosimilar (INB) in our diverse rheumatic cohort in daily clinical practice. All rheumatic patients on INX treatment (Remicade®) and ≥18 years were switched to INB (Inflectra®) as part of routine care, but in a controlled setting. Patients were monitored by taking blood samples just before the first infusion of INB (T1), and after the second (T2), fourth (T3), and seventh (T4) infusion of INB...
June 7, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28561325/assays-for-infliximab-drug-levels-and-antibodies-a-matter-of-scales-and-categories
#2
L Bader, S M Solberg, S H Kaada, N Bolstad, D J Warren, S Gavasso, C G Gjesdal, C A Vedeler
Immunogenicity is a frequent cause of secondary non-response to tumor necrosis factor (TNF) inhibitors. Drug level measurement and detection of anti-drug antibodies has been shown to be cost-effective and clinically relevant, and a large number of assays are available for these purposes. It is, however, difficult to compare assays and translate results into clinical meaningful information due to different methodological approaches and a lack of assay standardization. We have analyzed infliximab drug levels and anti-drug antibodies in 107 patient samples using enzyme-linked immunoassays (ELISA), immunofluorometric assays (IFMA), and reporter gene assays (RGA) for drug and for antibody...
May 31, 2017: Scandinavian Journal of Immunology
https://www.readbyqxmd.com/read/28513424/a-review-of-six-methods-for-monitoring-infliximab-concentrations-and-antibodies-to-infliximab%C3%A2
#3
Fang Cao, Hailong Cao, Xiaocang Cao
Anti-TNF-α therapy, such as infliximab (IFX), has profoundly changed treatment to induce and maintain remission for inflammatory bowel diseases patients who do not respond to conventional therapies. Unfortunately, IFX, as a chimeric protein, is potentially immunogenic, and antibodies to infliximab (ATI) may interfere with the pharmacodynamics and pharmacokinetics of the drug, thus resulting in a loss of response for a substantial proportion of patients. The clinical efficacy of IFX is correlated with the levels of IFX and ATI...
May 17, 2017: International Journal of Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28498155/therapeutic-drug-monitoring-to-guide-infliximab-dose-adjustment-is-associated-with-better-endoscopic-outcomes-than-clinical-decision-making-alone-in-active-inflammatory-bowel-disease
#4
Orlaith B Kelly, Sarah Oʼ Donnell, Joanne M Stempak, A Hillary Steinhart, Mark S Silverberg
BACKGROUND: Adequate infliximab (IFX) levels are associated with favorable outcomes in inflammatory bowel disease. Using therapeutic drug monitoring (TDM) to guide dosing is cost effective and associated with clinical improvement, but effect on endoscopic outcomes remains unclear. METHODS: Primary responders to IFX who underwent dose escalation (2008-2014) were reviewed. Patients with active endoscopic disease were included. Two cohorts were examined: TDM-based decision to escalate (TDM) and clinical decision (non-TDM)...
July 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28472597/golimumab-for-the-treatment-of-ulcerative-colitis
#5
Mathurin Flamant, Stephane Paul, Xavier Roblin
Tumor necrosis factor antagonists have revolutionized the therapeutic management of inflammatory bowel disease. Infliximab and adalimumab were the first biological agents used to induce and maintain remission in ulcerative colitis. More recently, a third tumor necrosis factor antagonist, golimumab, was approved, extending the therapeutic approach for moderate-to-severe ulcerative colitis. Areas covered: In this review, the authors review the literature on the efficacy and safety of golimumab in the context of other anti-TNF agents used in the treatment of this disease...
July 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28444562/infliximab-maintenance-dosing-in-inflammatory-bowel-disease-an-example-for-in-silico-assessment-of-adaptive-dosing-strategies
#6
Jessica Wojciechowski, Richard N Upton, Diane R Mould, Michael D Wiese, David J R Foster
Infliximab is an anti-tumour necrosis factor alpha monoclonal antibody used to treat inflammatory diseases. Many patients fail during induction and others respond initially but relapse during maintenance therapy. Although anti-drug antibodies (ADA) are associated with some clinical failures, there is evidence that some failures may be due to subtherapeutic exposure. Adapting doses based on clinical outcomes and trough concentrations can improve response and reduce the proportion that develop ADA, but identification of appropriate doses in the presence of time-varying patient factors is complicated...
April 25, 2017: AAPS Journal
https://www.readbyqxmd.com/read/28374338/therapeutic-drug-monitoring-of-golimumab-in-the-treatment-of-ulcerative-colitis
#7
REVIEW
Niels Vande Casteele, Reena Khanna
Ulcerative colitis (UC) is a relapsing-remitting chronic inflammatory disorder affecting the mucosal surface in a continuous manner from the rectum through part of, or the entire, colon. Patients with severe disease and those who become refractory or intolerant to corticosteroids and/or immunosuppressants, require treatment with biologic agents that target tumor necrosis factor-α (TNF). Golimumab, a fully human monoclonal antibody, is the latest TNF antagonist to get approved for the treatment of moderate-to-severe UC...
April 3, 2017: Pharmaceutical Research
https://www.readbyqxmd.com/read/28370040/editorial-infliximab-trough-cut-off-for-perianal-crohn-s-disease-another-piece-of-the-therapeutic-drug-monitoring-guided-infliximab-dosing-puzzle
#8
EDITORIAL
N Mitrev, V Kariyawasam, R W Leong
No abstract text is available yet for this article.
May 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28365486/improved-long-term-outcomes-of-patients-with-inflammatory-bowel-disease-receiving-proactive-compared-with-reactive-monitoring-of-serum-concentrations-of-infliximab
#9
Konstantinos Papamichael, Karen A Chachu, Ravy Vajravelu, Byron P Vaughn, Josephine Ni, Mark T Osterman, Adam S Cheifetz
BACKGROUND & AIMS: Monitoring serum concentrations of tumor necrosis factor antagonists in patients receiving these drugs as treatment for inflammatory bowel disease (IBD), also called therapeutic drug monitoring, is performed either after patient loss of response (reactive drug monitoring) or in patients in clinical remission whose drug has been titrated to a target concentration (proactive drug monitoring). We compared long-term outcomes of patients with IBD undergoing proactive vs reactive monitoring of serum concentrations of infliximab...
March 30, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28318043/the-effects-of-pregnancy-on-the-pharmacokinetics-of-infliximab-and-adalimumab-in-inflammatory-bowel-disease
#10
C H Seow, Y Leung, N Vande Casteele, E Ehteshami Afshar, D Tanyingoh, G Bindra, M J Stewart, P L Beck, G G Kaplan, S Ghosh, R Panaccione
BACKGROUND: Transplacental transfer of infliximab and adalimumab results in detectable drug levels in the cord blood and infant. AIM: To determine if pregnancy influenced the pharmacokinetics of anti-TNF agents in women with inflammatory bowel disease. METHODS: Twenty-five women from the University of Calgary inflammatory bowel disease(IBD) pregnancy clinic on maintenance infliximab or adalimumab were recruited prospectively with serum bio-banking performed each trimester...
May 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28286562/golimumab-pharmacokinetics-in-ulcerative-colitis-a-literature-review
#11
REVIEW
Ines Harzallah, Josselin Rigaill, Nicolas Williet, Stephane Paul, Xavier Roblin
Golimumab (GLM) is the latest anti-tumor necrosis factor (TNF) that gained its marketing license. Thanks to the PURSUIT induction and maintenance trials, it was approved for the treatment of ulcerative colitis (UC) in 2013. The other anti-TNF drugs available are infliximab and adalimumab. These two drugs have validated algorithms concerning prescription and therapeutic drug monitoring (TDM) but little is known about GLM. The available data on GLM's exposure-response relationship in UC are from the PURSUIT trials and are recently published...
January 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28222600/immunoassay-for-detection-of-infliximab-in-whole-blood-using-a-fiber-optic-surface-plasmon-resonance-biosensor
#12
Jiadi Lu, Dragana Spasic, Filip Delport, Thomas Van Stappen, Iris Detrez, Devin Daems, Séverine Vermeire, Ann Gils, Jeroen Lammertyn
Monitoring the concentration of a therapeutic drug antibody, infliximab (IFX), is recommended for enhancing its efficacy in patients with inflammatory bowel disease (IBD). However, IFX concentrations are currently determined in patients' serum/plasma, which requires sample preparation from blood, hence hampering the turnaround time. In this paper, we present a short immunoassay (10 min) using a fiber-optic surface plasmon resonance (FO-SPR) biosensor for detection of IFX spiked in 100-fold diluted serum, plasma, and whole blood...
March 3, 2017: Analytical Chemistry
https://www.readbyqxmd.com/read/28175214/p584-a-role-for-therapeutic-drug-monitoring-during-infliximab-induction-treatment-in-inflammatory-bowel-disease
#13
M Rasmussen, J Brynskov, M A Ainsworth, S Buhl, K Bendtzen, C Steenholdt
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175187/p586-a-novel-approach-to-the-implementation-of-biosimilar-infliximab-ct-p13-for-the-treatment-of-ibd-utilising-therapeutic-drug-monitoring-the-edinburgh-experience
#14
N Plevris, A Deekae, G R Jones, T A Manship, C L Noble, J Satsangi, A G Shand, I D Arnott, C W Lees
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175156/p645-the-introduction-of-infliximab-therapeutic-drug-level-monitoring-for-is-associated-with-cost-savings-in-a-cohort-of-patients-in-a-large-district-general-hospital
#15
S Whiteoak, H Johnson, C Hovell, S Weaver, S McLaughlin
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175101/p440-therapeutic-drug-monitoring-of-infliximab-for-the-management-of-loss-of-response-in-inflammatory-bowel-disease-an-observational-multicenter-study
#16
D Pugliese, A Armuzzi, T Panici Tonucci, B Tolusso, C Felice, A Papa, L Cantoro, P Balestrieri, F Civitelli, L Bertani, A Kohn, M Cicala, F Viola, F Costa, G L Rapaccini, L Guidi
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175050/p280-therapeutic-drug-monitoring-of-infliximab-and-adalimumab-for-detection-of-patients-at-risk-of-loss-of-response-in-inflammatory-bowel-disease
#17
J Gonzalez-Lopez, J M Giráldez-Montero, R Ferreiro, A Lorenzo, M J Lamas, J E Dominguez-Munoz, M Barreiro-de Acosta
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175042/p248-the-new-infliximab-point-of-care-quantitative-test-can-equally-be-used-for-therapeutic-drug-monitoring-of-biosimilars-of-infliximab
#18
J Afonso, H T Sousa, I Rosa, J Carvalho, C C Dias, F Magro
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28173072/p648-the-impact-of-infliximab-therapeutic-drug-monitoring-on-decisions-made-in-a-virtual-biologics-clinic-for-ibd
#19
C Selinger, M Lenti, T Clark, H Rafferty, A O'Connor, T Ahmad, J Hamlin
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172976/p591-therapeutic-drug-monitoring-in-paediatric-inflammatory-bowel-disease-on-maintenance-infliximab-and-adalimumab-treatment-improves-clinical-remission-with-a-proactive-approach
#20
S Chadokufa, S Sider, B Huggett, T Sawney, N Shah, M Baycheva, A Zambrano Perez, N Acton, F Kiparissi
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
keyword
keyword
83590
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"